A generative AI design system, paired with an in-house wet lab in a continuous feedback loop — producing novel RNA candidates faster, cheaper, and with greater precision than any existing approach.
Traditional RNA therapeutic development relies on iterative screening, trial-and-error synthesis, and expensive wet lab cycles that can take years to yield a viable candidate. The tools that exist today predict — they don’t design. Novarna was built to change that.
The Novarna platform is built on two complementary pillars: NovaEngine™ (AI design system) and NovaLab™ (wet lab validation infrastructure). Together, they form a closed feedback loop that gets smarter with every cycle.
Our 4th-generation AI, purpose-built for RNA. Generates entirely novel RNA sequences optimized for a target from the ground up.
Our in-house wet lab generates proprietary experimental data that trains the AI on real-world biological feedback.
Every experiment NovaLab runs becomes training signal. The platform gets better every time it works.
Focused pilot against a specific target. Ideal for proof-of-concept and platform validation.
Extended design and validation cycles delivering optimized, preclinical-ready candidates.
Multi-year co-development with milestone and royalty structures aligned from discovery through commercialization.
Novarna partnered with the University of Michigan DiFeo Lab to design RNA candidates against a live ovarian cancer target. The DiFeo Lab tested them in their own facility. The designs outperformed a commercially available treatment for the same target, and produced new molecule types with patent potential.
Wet lab results — confirmed by the DiFeo Lab at the University of Michigan. Not a simulation. Not self-reported.
Share your target with our science team — we’ll scope a program against your specific biology.